Tag
The VESALIUS-CV trial demonstrates that evolocumab lowers all-cause and cardiovascular mortality in patients with high cardiovascular risk but no prior myocardial infarction or stroke, highlighting its survival benefits in primary preventio
Elevated parathyroid hormone at the high-normal range independently predicts greater cardiovascular and all-cause mortality, with marked sex and age disparities in a large middle-aged Brazilian cohort.
Evidence reveals that both extreme cold and heat significantly trigger acute heart failure decompensation, with risk sensitivity varying by age and hemodynamic phenotype, necessitating targeted clinical prevention.
This review analyzes multinational data showing a significant decline in cardiovascular mortality among diabetes patients, alongside a concerning rise in dementia-related deaths and the emergence of cancer as a leading cause of mortality in
A 21-year longitudinal study reveals that blunted circadian heart rate variability and nocturnal dipping are independent predictors of cardiovascular and all-cause mortality in type 1 and type 2 diabetes, offering a low-cost risk stratifica
A landmark post-hoc analysis of the DPPOS and DaQing studies reveals that achieving prediabetes remission reduces the risk of cardiovascular death and heart failure hospitalization by approximately 50% over three decades, highlighting a pro
This multi-national analysis of 2.92 million deaths highlights a concerning trend: while coronary and stroke mortality have plummeted, heart failure mortality remains stagnant or rising, with people with diabetes bearing a disproportionate
Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.
This study finds an unexpected association between low levels of apolipoprotein B and LDL-cholesterol with increased all-cause and cardiovascular mortality, highlighting the complex role of lipid markers in mortality risk assessment.
Withdrawal of renin-angiotensin inhibitors and mineralocorticoid receptor antagonists in patients with heart failure and improved ejection fraction significantly increases 1-year cardiovascular mortality and hospitalization risks; beta-bloc
